Pfizer Nutrition Business Could Fit Nestle

Nestle SA (NESN.VX) is rumored to be among the potential buyers for Pfizer Inc.'s (PFE) nutrition business after the U.S. pharmaceutical company said it was exploring strategic options for the unit.

Nestle, along with Danone SA (BN.FR), Abbott Laboratories (ABT) and Mead Johnson Nutrition Co. (MJN) are among the companies to have been linked with the Pfizer unit, which analysts value at $7.8 billion to $10.4 billion.

A purchase by Nestle would help it improve margins at its own nutrition business, which generated sales of 10.8 billion Swiss francs ($13.49 billion) in 2010, said Bank Vontobel analyst Jean-Philippe Bertschy.

Currently the business has margins of around 19% but it wants to increase them further in the next two or three years.

The Pfizer business, which generated sales of $1.8 billion in 2010 and had a profit margin of 20% to 25%, could also bolster the position of Nestle's infant nutrition business in Asia, Bertschy added.

The Pfizer business has an 11% share of the Chinese market--bigger than Nestle--and 16% in Hong Kong.

"A purchase by Nestle would help Nestle secure its No. 1 position," said Bertschy. "Thanks to synergies, Nestle might be able to get margins in excess of 20%."

Nestle was also more able to afford the cost than its rivals, he added.

"We might have some antitrust concerns, but I don't think this will be a major concern. I think Nestle would be prepared to sell some businesses in some countries."

Nestle spokeswoman Melanie Kohli said, "As a matter of principle we do not comment on market rumors."

-By John Revill, Dow Jones Newswires; [phone] ; [e-mail]